NEWS

Vesalio Reports 2,500 Patient Milestone

Nashville, TN, December 7, 2020 - Vesalio reports it has surpassed 2,500 clinical cases with the NeVa™ neuro-thrombectomy platform.  Physicians have evaluated the Neva Drop Zone™ technology with enthusiasm as it has shown a unique capability of removing the full spectrum of clot types in large vessel occlusion ischemic stroke. 

CERENOVUS Launches NIMBUS™ Geometric Clot Extractor to Remove Tough Clots

IRVINE, CA – October 7, 2020 – CERENOVUS, part of Johnson & Johnson Medical Devices Companies*, today announced the European launch of CERENOVUS NIMBUS™, designed to remove tough clots for successful revascularization in patients with acute ischemic stroke caused by a large vessel occlusion.

MicroVention-Terumo announces new leadership: the company appoints new P...

Aliso Viejo, CA. – September 22, 2020 –MicroVention, Inc., a U.S. based subsidiary of Terumo and leading global neurovascular company, announced today the appointment of a new President and CEO, Mr. Carsten Schroeder. The MicroVention acting President and CEO, Kazuaki Kitabatake, who has been in his role since August 2019, will continue as Chairman of the Board for MicroVention.  Mr. Schroeder will assume this position with MicroVention in early November 2020. 

Vesalio Expands Sales Network, Initiates Virtual Physician Training and...

Vesalio announces it has executed additional exclusive distribution agreements in Europe, Latin America, Asia, and the Middle East. With these new partnerships, the NeVa™ Thrombectomy System has gained market coverage in 53 countries.

CERENOVUS Launches New Suite of Technologies to Advance Stroke Treatment

IRVINE, CA – September 9, 2020 – CERENOVUS, part of Johnson & Johnson Medical Devices Companies* today announced that it has launched CERENOVUS Stroke Solutions™, which includes a suite of three devices designed to aid physicians in clot removal procedures. The announcement was made during the virtual European Society of Minimally Invasive Neurological Therapy (ESMINT).

Wallaby Medical Raises over $20M in Series B+ Financing to Accelerate De...

The new funding will promote the development of a global hemorrhagic and ischemic stroke treatment product portfolio, as well as support the company’s two ongoing clinical trials.

Cerus Endovascular and Balt Enter Strategic Distribution Agreement for I...

FREMONT, Calif. and OXFORD, United Kingdom and MONTMORENCY, France, Cerus Endovascular Ltd., a privately-held, commercial-stage medical device company and AB Medica Deutschland Verwaltungs GmbH, a wholly owned subsidiary of Balt, today announced that they have entered into a strategic distribution agreement providing AB Medica with the exclusive rights to market and sell the newly CE marked Contour Neurovascular System™ and the Neqstent Coil Assisted Flow Diverter devices in Germany. Terms of the agreement were not disclosed.

Cerus Endovascular Receives CE Mark Approval for its CerusEndo MC 021 Mi...

Commercial Sales Across European Union Expected to Begin During Fourth Quarter of 2020

European launch of NEW pRESET 5-40 & pRESET LUX thrombectomy devices

Phenox today announced the full European launch of the pRESET 5-40 and pRESET LUX 4-20 thrombectomy devices after receiving CE mark approval last year.

Granted reimbursement of the Silk+ flow diverter on the French market

Balt is thrilled to announce today, the Silk+ reimbursement has been granted on the French market.